Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855390 | 0.84 | DPP4 (0.43) | — | |
| SCHEMBL28367268 | 0.82 | FDPS (0.47) | ALDH1A1SMN1; SMN2FDPSTSHR | |
| SCHEMBL1823104 | 0.82 | TSHR (0.38) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL27878198 | 0.81 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2FDPS | |
| SCHEMBL765944 | 0.78 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL4883951 | 0.75 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2FDPSLMNAHSD17B10 | |
| Bromide SCHEMBL9486965 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4888576 | 0.74 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2FDPSLMNAHSD17B10 | |
| SCHEMBL6542741 | 0.74 | — | — | |
| SCHEMBL30393366 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8409673-B2 | Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device | JNC CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433923-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL ELEMENT | JNC Corporation (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | CRYAB, CYBA, CCNB1 | ALDH1A1 2136/4885SMN1; SMN2 4881/4885FDPS 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.